Response to alpha-interferon in children with Philadelphia chromosome-positive chronic myelocytic leukemia
β Scribed by Lois W. Dow; Susana C. Raimondi; Steven J. Culbert; Judith Ochs; Wren Kennedy; Donald P. Pinkel
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- English
- Weight
- 634 KB
- Volume
- 68
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The prognostic value of several clinical and hematologic features, recorded at diagnosis, in chronic phase Ph' positive chronic myelocytic leukemia (CML), was analyzed in 135 patients using life-table analysis. About one third of patients were atomic bomb survivors and they had been examined twice a
In a pilot study, 32 patients with Philadelphia chromosome-positive chronic myelogenous leukemia were treated with intensive chemotherapy induction followed by interferon-alpha (IFN-A) maintenance. Intensive chemotherapy consisted of three cycles of daunorubicin 120 mg/mz on day 1, cytarabine 80 mg/
## Abstract A female patient with chronic myelocytic leukemia (CML) in chronic phase after busulfan and interferon treatment had four different cell lines in her bone marrow. In addition to cells with a normal karyotype there were cells with the Philadelphia chromosome (Ph^1^), cells with trisomy 8
## Abstract ## BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)βnegative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib. This phenomenon